Detection of GSTP1 methylation in all types of body fluids of prostate cancer patients represents a promising epigenetic biomarker, while the unmethylated promoter allowed to distinguish benign lesions from cancerous transformations [120]. Here, GSTP1 is linked to prostate cancer.